Michelle Afkhami, MD, of City of Hope, joins The American Journal of Managed Care® (AJMC®) for a discussion on EGFR exon 20 insertion positive mutations in non-small cell lung cancer. Michelle Afkhami ...

If your doctor thinks you have non-small-cell lung cancer (NSCLC), they will usually look for a change (they may call it a mutation) in a gene called the EGFR gene. Normally, EGFR helps healthy cells ...

Activating mutations on the EGFR protein, including exon 20 insertion mutations, have a role in NSCLC, but the associated structural changes resulting from the V769insASV and D770insNPG EGFR exon 20 ...

Christopher Arendt, PhD, head of the Oncology Therapeutic Area Unit at Takeda, discusses pathogenesis and characteristics of EGFR exon 20 mutations in metastatic non–small cell lung cancer (NSCLC).

EGFR exon 20 insertion (EGFRex20ins) mutations are uncommon mutations in non-small cell lung cancer (NSCLC) that are associated with resistance to TKI therapy. Although two new targeted therapies have ...

Experts explain the presence and role of EGFR exon 20 insertion mutations in non–small cell lung cancer and highlight the role of molecular profiling. Shared insight on how molecular profiling can ...

Characterization of heart rate (HR) changes during crizotinib treatment: A retrospective analysis of 1,053 ALK+ NSCLC patients. Clinical impact of gastric acid suppressing medication use on the ...